Autolus Therapeutics (NASDAQ:AUTL) Raised to Strong-Buy at Truist Financial

Autolus Therapeutics (NASDAQ:AUTL) was upgraded by investment analysts at Truist Financial to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

Other equities research analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, January 21st. HC Wainwright initiated coverage on shares of Autolus Therapeutics in a report on Tuesday, February 17th. They issued a “buy” rating and a $9.00 price target for the company. Needham & Company LLC lowered their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, January 12th. Finally, Zacks Research raised Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, March 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Autolus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

Autolus Therapeutics Price Performance

Shares of NASDAQ:AUTL opened at $1.29 on Wednesday. The firm’s 50 day simple moving average is $1.49 and its 200 day simple moving average is $1.52. Autolus Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $2.70. The company has a market capitalization of $343.32 million, a price-to-earnings ratio of -1.55 and a beta of 1.95.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AUTL. Mak Capital One LLC raised its holdings in shares of Autolus Therapeutics by 53.5% during the third quarter. Mak Capital One LLC now owns 26,017,616 shares of the company’s stock worth $42,409,000 after acquiring an additional 9,062,518 shares during the period. Armistice Capital LLC boosted its stake in Autolus Therapeutics by 9.1% in the 2nd quarter. Armistice Capital LLC now owns 12,000,000 shares of the company’s stock worth $27,360,000 after purchasing an additional 1,000,000 shares during the period. TFG Asset Management GP Ltd increased its holdings in Autolus Therapeutics by 10.5% during the 2nd quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock worth $21,660,000 after purchasing an additional 900,000 shares in the last quarter. Cetera Investment Advisers raised its stake in shares of Autolus Therapeutics by 17.6% in the 2nd quarter. Cetera Investment Advisers now owns 617,172 shares of the company’s stock valued at $1,407,000 after purchasing an additional 92,300 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Autolus Therapeutics in the 2nd quarter valued at about $1,288,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.